Newsletter Tool

PM Tracker

Today’s Big News

Aug 5, 2024

Bristol Myers telegraphs layoffs in New Jersey, trimming 117 jobs in staggered wave of cuts

Introducing Fierce Biotech's 2024 Fierce 15

Testmaker Cepheid to cut more than 600 jobs at Silicon Valley headquarters

3 Big Pharma companies, 33 phase 3 trials: The race for supremacy in an ADC field

BioNTech ends work on Genmab-partnered bispecific antibody acasunlimab

Featured

Bristol Myers telegraphs layoffs in New Jersey, trimming 117 jobs in staggered wave of cuts

By Angus Liu

Bristol Myers Squibb, while working its way through a major restructuring, has unveiled another round of layoffs in its home state of New Jersey.

Introducing Fierce Biotech's 2024 Fierce 15

By Annalee Armstrong

This year's Fierce 15 features companies pushing the envelope in the lab, clinic and boardroom.

Testmaker Cepheid to cut more than 600 jobs at Silicon Valley headquarters

By Heather Landi

Testmaker Cepheid plans to eliminate 626 staff positions at its Sunnyvale, California headquarters by September 27, according to a regulatory filing.

3 Big Pharma companies, 33 phase 3 trials: The race for supremacy in an ADC field

By Angus Liu

On June 14, Merck & Co. posted a new entry on ClinicalTrials.gov. The study marked the 10th global phase 3 trial that the New Jersey pharma has logged for its Kelun Biotech-partnered ADC, sacituzumab tirumotecan, in about eight months. And Merck isn’t finished.

BioNTech ends work on Genmab-partnered bispecific antibody acasunlimab

By James Waldron

BioNTech may still claim that the bispecific antibody acasunlimab has an “encouraging” clinical profile, but the mRNA leader has opted to end its involvement and allow partner Genmab to go solo for phase 3 trials.

Eli Lilly's Mounjaro, Zepbound back in stock after extended shortage, FDA says

By Zoey Becker

The update to Lilly's supply woes come after the company's popular tirzepatide-based meds have been in shortage for months due to rampant demand.

'Clinical intuition' led FDA advisors to back Zevra's rare disease med

By Annalee Armstrong

Zevra Therapeutics’ rare disease drug seems to be on the path to approval this fall after gaining the backing of an FDA advisory committee, although the experts were split, with some voting yes simply to address an unmet need.

Bayer's Kerendia passes key test, cutting risk of cardio death and heart failure

By Kevin Dunleavy

In a phase 3 trial, Bayer's Kerendia has shown it can reduce the risk of cardiovascular death, as well as first and recurrent heart failure events, in HF patients with mildly reduced or preserved ejection fraction.

Fierce podcasts

Don’t miss an episode

What 'The Next Berlin Patient' and a PrEP’s 100% efficacy mean for HIV drug development

This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany.

Fierce 15: Where are they now?

Championing equity in skin of color dermatology

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.